G T Gibney1, S A Aziz2, R L Camp3, P Conrad2, B E Schwartz4, C R Chen4, W K Kelly5, H M Kluger2. 1. Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa. Electronic address: geoffrey.gibney@moffitt.org. 2. Section of Medical Oncology, Yale Cancer Center. 3. Department of Pathology, Yale University School of Medicine, New Haven. 4. Clinical Development, ArQule, Inc., Woburn. 5. Departments of Medical Oncology and Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA.
Abstract
BACKGROUND: Activation of the c-Met pathway occurs in a range of malignancies, including papillary renal cell carcinoma (RCC). Its activity in clear cell RCC is less clear. We investigated c-Met expression and inhibition in a large cohort of RCC tumors and cell lines. METHODS: c-Met protein expression was determined by automated quantitative analysis (AQUA) on a tissue microarray (TMA) constructed from 330 RCC tumors paired with adjacent normal renal tissue. c-Met expression and selective inhibition with SU11274 and ARQ 197 were studied in clear cell RCC cell lines. RESULTS: Higher c-Met expression was detected in all RCC subtypes than in the adjacent normal renal tissue (P < 0.0001). Expression was highest in papillary and sarcomatoid subtypes, and high-grade and stage tumors. Higher c-Met expression correlated with worse disease-specific survival [risk ratio = 1.36; 95% confidence interval (CI) 1.08-1.74; P = 0.0091] and was an independent predictor of survival, maintained in clear cell subset analyses. c-Met protein was activated in all cell lines, and proliferation (and colony formation) was blocked by SU11274 and ARQ 197. CONCLUSIONS: c-Met is associated with poor pathologic features and prognosis in RCC. c-Met inhibition demonstrates in vitro activity against clear cell RCC. Further study of ARQ 197 with appropriate biomarker studies in RCC is warranted.
BACKGROUND: Activation of the c-Met pathway occurs in a range of malignancies, including papillary renal cell carcinoma (RCC). Its activity in clear cell RCC is less clear. We investigated c-Met expression and inhibition in a large cohort of RCC tumors and cell lines. METHODS:c-Met protein expression was determined by automated quantitative analysis (AQUA) on a tissue microarray (TMA) constructed from 330 RCC tumors paired with adjacent normal renal tissue. c-Met expression and selective inhibition with SU11274 and ARQ 197 were studied in clear cell RCC cell lines. RESULTS: Higher c-Met expression was detected in all RCC subtypes than in the adjacent normal renal tissue (P < 0.0001). Expression was highest in papillary and sarcomatoid subtypes, and high-grade and stage tumors. Higher c-Met expression correlated with worse disease-specific survival [risk ratio = 1.36; 95% confidence interval (CI) 1.08-1.74; P = 0.0091] and was an independent predictor of survival, maintained in clear cell subset analyses. c-Met protein was activated in all cell lines, and proliferation (and colony formation) was blocked by SU11274 and ARQ 197. CONCLUSIONS:c-Met is associated with poor pathologic features and prognosis in RCC. c-Met inhibition demonstrates in vitro activity against clear cell RCC. Further study of ARQ 197 with appropriate biomarker studies in RCC is warranted.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: Lecia V Sequist; Joachim von Pawel; Edward G Garmey; Wallace L Akerley; Wolfram Brugger; Dora Ferrari; Yinpu Chen; Daniel B Costa; David E Gerber; Sergey Orlov; Rodryg Ramlau; Susan Arthur; Igor Gorbachevsky; Brian Schwartz; Joan H Schiller Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Patrick Schöffski; Jorge A Garcia; Walter M Stadler; Thierry Gil; Eric Jonasch; Scott T Tagawa; Melanie Smitt; Xinqun Yang; Kelly S Oliner; Abraham Anderson; Min Zhu; Fairooz Kabbinavar Journal: BJU Int Date: 2010-12-13 Impact factor: 5.588
Authors: Lee S Rosen; Neil Senzer; Tarek Mekhail; Ram Ganapathi; Feng Chai; Ronald E Savage; Carol Waghorne; Giovanni Abbadessa; Brian Schwartz; Robert Dreicer Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531
Authors: Harriet M Kluger; Summar F Siddiqui; Cesar Angeletti; Mario Sznol; William K Kelly; Annette M Molinaro; Robert L Camp Journal: Lab Invest Date: 2008-07-14 Impact factor: 5.662
Authors: Ro Ra Oh; Jik Young Park; Jong Heun Lee; Min Sun Shin; Hong Sug Kim; Sang Kyu Lee; Young Sil Kim; Sug Hyung Lee; Sie Nae Lee; Young Mok Yang; Nam Jin Yoo; Jung Young Lee; Won Sang Park Journal: APMIS Date: 2002-03 Impact factor: 3.205
Authors: James G Christensen; Randall Schreck; Jon Burrows; Poonam Kuruganti; Emily Chan; Phuong Le; Jeffrey Chen; Xueyan Wang; Lany Ruslim; Robert Blake; Kenneth E Lipson; John Ramphal; Steven Do; Jingrong J Cui; Julie M Cherrington; Dirk B Mendel Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris Journal: J Clin Oncol Date: 2016-11-14 Impact factor: 44.544
Authors: Murugabaskar Balan; Eduardo Mier y Teran; Ana Maria Waaga-Gasser; Martin Gasser; Toni K Choueiri; Gordon Freeman; Soumitro Pal Journal: J Biol Chem Date: 2015-02-02 Impact factor: 5.157
Authors: Meaghan L Barr; Lucia B Jilaveanu; Robert L Camp; Adebowale J Adeniran; Harriet M Kluger; Brian Shuch Journal: J Clin Pathol Date: 2014-10-14 Impact factor: 3.411
Authors: David Cella; Bernard Escudier; Nizar M Tannir; Thomas Powles; Frede Donskov; Katriina Peltola; Manuela Schmidinger; Daniel Y C Heng; Paul N Mainwaring; Hans J Hammers; Jae Lyun Lee; Bruce J Roth; Florence Marteau; Paul Williams; John Baer; Milan Mangeshkar; Christian Scheffold; Thomas E Hutson; Sumanta Pal; Robert J Motzer; Toni K Choueiri Journal: J Clin Oncol Date: 2018-01-29 Impact factor: 44.544